Results 301 to 310 of about 1,005,341 (342)
Some of the next articles are maybe not open access.

Related searches:

CCR1 antagonists

Molecular Diversity, 2008
CCR1 (CC Chemokine receptor 1) is a widely studied G protein-coupled receptor target expressed on multiple types of leukocytes. It is implicated in initiating and exacerbating inflammatory conditions and thus is viewed as a good target for autoimmune and inflammatory therapeutic applications. Numerous CCR1 antagonists have been reported.
Rick Jack, Jie-Fei Cheng
openaire   +3 more sources

VEGF antagonists

Expert Opinion on Biological Therapy, 2001
The majority of cancer have an absolute requirement for angiogenesis, the process by which new blood vessels are formed. The most potent angiogenic cytokine is vascular endothelial growth factor (VEGF) and there has been substantial research into the development of VEGF/VEGF receptor (VEGFR) antagonists.
Hasan, J, Jayson, G
openaire   +3 more sources

Vasopressin antagonists

Cellular and Molecular Life Sciences, 2006
Effects of vasopressin via V1a- and V2-receptors are closely implicated in a variety of water-retaining diseases and cardiovascular diseases, including heart failure, hyponatraemia, hypertension, renal diseases, syndrome of inappropriate antidiuretic hormone secretion, cirrhosis and ocular hypertension.
Lemmens, Rosa, Kamyar, Majid-Reza
openaire   +2 more sources

Antagonists of bacitracin

Letters in Applied Microbiology, 1994
Three groups of substances were identified which inhibit the bactericidal activity of bacitracin. Beside two divalent metals, Mg2+ and Ca2+, and a metabolite with chelating properties, citrate, the most pronounced effect was observed with pyrophosphate. Metals probably prevent access of bacitracin to the lipid carrier whereas metabolites with chelating
Z. Podlesek, A. Comino
openaire   +3 more sources

Potentiation by an Antagonist

Nature, 1969
IF drugs b and c are competitive antagonists of drug a, then it would seem self evident that the addition of c to a system in which b was already present would increase the degree of block. But where the receptors are exposed to the agonist for only a short time there is another possibility. If the first antagonist dissociates from the receptors slowly,
R P Stephenson, B. L. Ginsborg
openaire   +3 more sources

Home - About - Disclaimer - Privacy